Metastases

Type: Keyphrase
Name: Metastases
First reported 5 hours ago - Updated 5 hours ago - 1 reports

Cancer Spread’s ‘Family Tree’

The process of metastasis— a tumor’s ability to spread to other parts of the body— is still poorly understood. It has not been easy to determine whether metastasis began early or late in the development of the primary tumor, or whether individual metastatic ... [Published Bioscience Technology Online - 5 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Fast simple-to-use assay reveals family tree of cancer metastases

A simple assay that can reveal the evolutionary relationships between primary tumors and metastases within a patient has been developed. The information gathered may someday help with treatment ... ... [Published Big News Network - 12 hours ago]
First reported 22 hours ago - Updated 22 hours ago - 1 reports

The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer - Abstract

BACKGROUND: In the prostate-specific antigen (PSA) screening era, approximately 15% of US men still present with clinically high-risk prostate cancer (PC).However, high-risk PC may be downgraded/downstaged at radical prostatectomy (RP), making additional ... [Published UroToday - 22 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Killing Cancer on the Run

A dream solution to cancer metastasis has been to develop a method that can track and kill the cancer cells that are on the move. The complexity at which those cancer cells operate– they not only move around but they fly under the radar of the immune ... [Published Bioscience Technology Online - 23 hours ago]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Prognosis favorable among patients with Thy 3 nodules

Rago T. J Clin Endocrinol Metab. 2014;doi:10.1210/jc.2013-4401.Patients with a thyroid nodule of indeterminate cytology and a histology of thyroid cancer have a good prognosis overall, according to findings published in The Journal of Clinical Endocrinology ... [Published Orthopedics Today - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Phylogenetic analysis in human colon cancer [Genetics]

Kamila Naxerova a , 1 , Elena Brachtel b , Jesse J. Salk c , Aaron M. Seese d , Karen Power d , Bardia Abbasi e , Matija Snuderl f , Sarah Chiang g , Simon Kasif h , i , and Rakesh K. Jain a a Edwin L. Steele Laboratory for Tumor Biology, Department ... [Published PNAS - Apr 22 2014]
First reported Apr 21 2014 - Updated Apr 22 2014 - 3 reports

Fast, simple-to-use assay reveals the 'family tree' of cancer metastases

The process of metastasis a tumor's ability to spread to other parts of the body is still poorly understood. It is not easy to determine whether metastasis began early or late in the development of the primary tumor or whether individual metastatic sites ... [Published Bio-Medicine - Apr 22 2014]
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

Nektar Presents Pipeline Data - Analyst Blog

By Zacks Equity ResearchNektar Therapeutics ( NKTR ) presented preclinical data on its oncology candidates, NKTR-102 (a novel next-generation topoisomerase I inhibitor) and NKTR-214, at the 2014 Annual Meeting of the American Association of Cancer Research ... [Published Mr Top Step - Apr 19 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Y-90 radioembolization: A new treatment for hepatic metastases from breast cancer

Share this article:Yttrium-90 (Y-90) radioembolization is a minimally invasive treatment that may slow disease progression in breast cancer that has metastasized to the liver. It delivers cancer-killing radiation directly to the tumor, sparing healthy ... [Published Chemotherapy Advisor - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Palliative Radiotherapy for Prostate Cancer

ABSTRACT: Radiotherapy is an effective tool for the palliation of symptoms commonly caused by prostate cancer. The majority of painful bone metastases respond equally well to single or multiple fractions of external radiotherapy. Retreatment with a second ... [Published Consultant Live - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

MEDICAL SCIENCES : Investigators from Poznan University of Medical Sciences Target Thyroid Cancer

By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology is now available. According to news originating from Poznan, Poland , by NewsRx correspondents, research stated, "The purpose of the study was to assess the feasibility of ... [Published 4 Traders - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 2 reports

NICE recommends FIRMAGON for treating advanced hormonedependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metas ... [Published BioPortfolio - Apr 16 2014]

Quotes

"The invention further provides kits for detecting the HTF9C, HER2 and/or ER markers, new therapeutic agents (e g., an antibody directed to HTF9C optionally associated with a cytotoxic agent) and methods for the treatment of HER2+ breast cancers."
...According to news reporting originating from College Park, Maryland , by NewsRx correspondents, research stated, "The main goal of treatment regimens for metastasis is to control growth rates, not eradicate all cancer cells. Mathematical models offer methodologies that incorporate high-throughput data with dynamic effects on net growth."
...colorectal cancers therapy, including two cases where IMMU-130 was able to shrink the patients' colonic cancer metastases 52% and 66%, respectively. "The second patient is being treated at our center for almost 9 months, receiving doses twice weekly during this time, without evidence of major side effects or any immune reaction to the ADC; the patients had 4 prior therapies before entering this trial" Dr. Guarino explained
"The STAND study results are encouraging as they provide additional evidence on how sipuleucel-T can be sequenced with other treatments which will assist clinician decision-making upon whether immune responses correlate with certain clinical parameters, such as prostate specific antigen (PSA) recurrence" said Neal Shore , M DD medicalmedical director at the Carolina Urologic Research Center

More Content

All (461) | News (419) | Reports (0) | Blogs (36) | Audio/Video (0) | Fact Sheets (2) | Press Releases (1)
sort by: Date | Relevance
Hemolytic Anemia and Metastatic Carcinoma: Case... [Published Lab Medicine - 1 hour ago]
Notch-1 Signaling Promotes the Malignant Featur... [Published PLoS medicine - 1 hour ago]
Patent Issued for Reagents and Methods for Use ... [Published HispanicBusiness.com - 3 hours ago]
Molecular Medicine : Investigators from Univers... [Published 4 Traders - 5 hours ago]
Cancer Spread’s ‘Family Tree’ [Published Bioscience Technology Online - 5 hours ago]
Immunomedics Highlights Clinical Pipeline for S... [Published Virtual Strategy Magazine - 5 hours ago]
DENDREON : Immune Responses Enhanced and Sustai... [Published 4 Traders - 6 hours ago]
Immunomedics Highlights Clinical Pipeline For S... [Published TheStreet.com - 6 hours ago]
Immunomedics : Highlights Clinical Pipeline for... [Published 4 Traders - 6 hours ago]
Longest Follow-Up to Date Shows Active Surveill... [Published CancerConnect.com - 7 hours ago]
Largest Prostate Screening Trial Still Shows it... [Published General Medicine eJournal - 9 hours ago]
Findings from G. Gaslini Children's Hospital Yi... [Published Pharmacy Choice - 11 hours ago]
Fast simple-to-use assay reveals family tree of... [Published Big News Network - 12 hours ago]
The impact of pathologic staging on the long-te... [Published UroToday - 22 hours ago]
Killing Cancer on the Run [Published Bioscience Technology Online - 23 hours ago]
Media alert: IMPAKT Breast Cancer Conference ab... [Published EurekAlert! - Apr 22 2014]
Prognosis favorable among patients with Thy 3 n... [Published Orthopedics Today - Apr 22 2014]
PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANN... [Published Yahoo! Finance - Apr 22 2014]
Advaxis receives notices of allowances for canc... [Published Individual.com - Apr 22 2014]
Phylogenetic analysis in human colon cancer [Ge... [Published PNAS - Apr 22 2014]
Fast, simple-to-use assay reveals the 'family t... [Published Bio-Medicine - Apr 22 2014]
Updated Summary: ACR Appropriateness Criteria® ... [Published National Guideline Clearinghouse - Apr 21 2014]
Updated Summary: ACR Appropriateness Criteria® ... [Published National Guideline Clearinghouse - Apr 21 2014]
Human Papillomavirus and Cystic Node Metastasis... [Published PLoS medicine - Apr 21 2014]
Fast simpletouse assay reveals the 'family tree... [Published BioPortfolio - Apr 21 2014]
Fast, simple-to-use assay reveals the 'family t... [Published Medical Xpress - Apr 21 2014]
Lumiphore receives SBIR grant to advances its s... [Published PharmaBiz - Apr 21 2014]
Nektar Presents Pipeline Data - Analyst Blog [Published Mr Top Step - Apr 19 2014]
Y-90 radioembolization: A new treatment for hep... [Published Chemotherapy Advisor - Apr 18 2014]
CD44 variant 6 is associated with prostate canc... [Published UroToday - Apr 18 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
UK NICE guidance recommends FIRMAGON® (degareli... [Published Business Wire Science: Science News - Apr 15 2014]
WEST DRAYTON, England--(BUSINESS WIRE)--The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON® (degarelix) as an option for treating advanced hormone-dependent prostate ...
UK NICE guidance recommends FIRMAGON® (degareli... [Published EON Science - Apr 15 2014]
WEST DRAYTON, England--(EON: Enhanced Online News)--The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON® (degarelix) as an option for treating advanced hormone-dependent ...
UK NICE guidance recommends FIRMAGON® (degareli... [Published Business Wire Health News - Apr 15 2014]
WEST DRAYTON, England--(BUSINESS WIRE)--The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON® (degarelix) as an option for treating advanced hormone-dependent prostate ...
NICE draft guidance recommends a treatment for ... [Published NICE | National Institute for Health and Clinic ... - Apr 15 2014]
In final draft guidance published today (15 April, 2014), NICE has recommended degarelix (Firmagon, Ferring Pharmaceuticals), as an option for treating advanced hormone dependent prostate cancer in people with spinal metastases who present with signs ...
Dendreon to present long-term Phase II STAND st... [Published PBR - News - Apr 14 2014]
Dendreon has announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when Provenge (sipuleucel-T) is given after androgen ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Myriad's Prolaris(R) Test Significantly Modifie... [Published GlobeNewswire: Acquisitions News - Jan 29 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.